SG11201803604UA - Methods and compositions for managing reproduction - Google Patents

Methods and compositions for managing reproduction

Info

Publication number
SG11201803604UA
SG11201803604UA SG11201803604UA SG11201803604UA SG11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA SG 11201803604U A SG11201803604U A SG 11201803604UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
managing reproduction
reproduction
managing
Prior art date
Application number
SG11201803604UA
Other languages
English (en)
Inventor
Nicolas Michel Orsi
Nadia Gopichandran
David Andrew Brooke
Original Assignee
Ostara Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ostara Biomedical Ltd filed Critical Ostara Biomedical Ltd
Publication of SG11201803604UA publication Critical patent/SG11201803604UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201803604UA 2015-10-05 2016-10-04 Methods and compositions for managing reproduction SG11201803604UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237017P 2015-10-05 2015-10-05
GBGB1517523.5A GB201517523D0 (en) 2015-10-05 2015-10-05 Methods and compositions for managing reproduction
PCT/GB2016/053080 WO2017060685A1 (en) 2015-10-05 2016-10-04 Methods and compositions for managing reproduction

Publications (1)

Publication Number Publication Date
SG11201803604UA true SG11201803604UA (en) 2018-05-30

Family

ID=54606069

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803604UA SG11201803604UA (en) 2015-10-05 2016-10-04 Methods and compositions for managing reproduction

Country Status (9)

Country Link
US (1) US10588944B2 (zh)
EP (1) EP3359127A1 (zh)
JP (1) JP2018531940A (zh)
CN (1) CN108289836A (zh)
AU (1) AU2016334795A1 (zh)
CA (1) CA3003668A1 (zh)
GB (2) GB201517523D0 (zh)
SG (1) SG11201803604UA (zh)
WO (1) WO2017060685A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
CN107099501B (zh) * 2017-05-27 2022-04-05 广东华农大资产经营有限公司 一种诱导幼龄灵长类动物获取性腺配子的方法和应用
CN107439411A (zh) * 2017-08-16 2017-12-08 杨旭升 一种基于活动量监测的牛发情揭发方法
CN110151354A (zh) * 2018-01-12 2019-08-23 塔里木大学 一种使发情期绵羊卵巢优势化卵泡数量增多的方法
CN109042515A (zh) * 2018-08-16 2018-12-21 阜阳师范学院 提高山羊体内早期胚胎附植数量和窝产仔数的方法
CN111249450A (zh) * 2020-01-20 2020-06-09 公安部南昌警犬基地 一种促进犬发情的药物组合物
CN111616830A (zh) * 2020-07-03 2020-09-04 宁夏大学 一种新型icr小鼠超数排卵方法
CN112715475B (zh) * 2020-12-28 2023-11-24 无锡珊瑚礁生物科技有限公司 一种提高雪貂产仔率的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563846B2 (zh) * 1972-10-12 1981-01-27
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
WO1996021427A1 (en) 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
AUPO550897A0 (en) 1997-03-06 1997-03-27 Luminis Pty Limited Treatment and diagnosis of an infertility condition
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
WO2000025780A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
WO2000068203A1 (fr) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Composes cycliques et leurs utilisations
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2002951531A0 (en) 2002-09-20 2002-10-03 The University Of Adelaide Treatment and diagnosis of an infertility condition by measuring or inhibiting interferon-y
NZ571243A (en) 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
EP3025722B1 (en) 2003-10-03 2020-05-27 Thorn BioScience, LLC Process for the synchronization of ovulation for timed breeding without heat detection
US8338373B2 (en) 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
WO2005115456A2 (en) 2004-05-28 2005-12-08 President And Fellows Of Harvard College METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY
PL1753456T3 (pl) 2004-06-10 2017-01-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
CN100431546C (zh) * 2005-07-07 2008-11-12 天津市中意畜牧科技发展有限公司 孕激素组合物及其缓释栓装置及该装置的制备
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
WO2007113682A2 (en) 2006-04-06 2007-10-11 Novozymes Gropep Ltd Tgf-beta pharmaceutical compositions
JP5240945B2 (ja) 2006-11-28 2013-07-17 ピクター リミテッド アッセイ膜およびその使用法
PT2101760E (pt) 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
WO2008070902A1 (en) 2006-12-11 2008-06-19 Novozymes Biopharma Au Limited Tgf-beta compositions for treating infertility
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
AU2008277730B2 (en) 2007-07-13 2013-01-31 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
KR101556269B1 (ko) 2007-08-29 2015-09-30 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제제
US8003324B2 (en) 2007-10-18 2011-08-23 U.S. Department Of Veterans Affairs Modulation of sodium channels by nicotinamide adenine dinucleotide
GB0806281D0 (en) 2008-04-07 2008-05-14 Univ Leeds Markers of Oocyte viability
EP2274325A4 (en) 2008-05-13 2011-05-25 Nora Therapeutics Inc ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010126528A1 (en) * 2009-05-01 2010-11-04 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
WO2010149597A2 (en) 2009-06-18 2010-12-29 Cellartis Ab 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
EP2462138B1 (en) 2009-08-05 2014-09-24 Versitech Limited Antiviral compounds and methods of making
US8882748B2 (en) * 2009-10-08 2014-11-11 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
BR112012029392A2 (pt) 2010-05-20 2017-07-11 Univ Saskatchewan uso d einibidores de aromatase para a sincronização da ovulação, indução da superovulação ou ovulação dupla e melhora da geminação e fertilidade em um mamífero
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
US9005108B2 (en) * 2012-09-27 2015-04-14 Palo Alto Research Center Incorporated Multiple reservoir drug delivery device and methods
ITMI20122063A1 (it) 2012-12-03 2014-06-04 Marco Sbracia Gm-csf per l'utilizzo nella prevenzione dell'aborto spontaneo e del fallimento dell'impianto dell'embrione
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
EP3074031A4 (en) * 2013-11-27 2017-08-09 JBS United Animal Health II LLC Method and composition for synchronizing time of insemination in gilts
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation

Also Published As

Publication number Publication date
WO2017060685A1 (en) 2017-04-13
GB201616851D0 (en) 2016-11-16
GB201517523D0 (en) 2015-11-18
JP2018531940A (ja) 2018-11-01
EP3359127A1 (en) 2018-08-15
US10588944B2 (en) 2020-03-17
GB2548649A (en) 2017-09-27
AU2016334795A1 (en) 2018-05-24
CN108289836A (zh) 2018-07-17
CA3003668A1 (en) 2017-04-13
US20170095536A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
HK1256817A1 (zh) 用於基因組編輯的組合物和方法
HK1252358A1 (zh) 用於確定倍性的方法及組合物
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
EP3379935A4 (en) METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
EP3328377A4 (en) COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGICAL THERAPIES
GB2546350B (en) Compositions and methods
GB2535253B (en) Compositions and methods
HK1251610A1 (zh) 用於抑制因子d的組合物和方法
GB201718876D0 (en) Antithrombin-heparin compositions and methods
GB201616851D0 (en) Methods and compositions for managing reproduction
IL258292A (en) Methods and compositions for reducing metastases
IL268684A (en) Preparations and methods for immuno-oncology
IL246879A0 (en) Preparations of Epilimod and methods of using them
GB201417828D0 (en) New methods and compositions
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
HK1246193A1 (zh) 用於改善認知的方法和組合物
IL274524A (en) Preparations and methods for aquaculture
HK1254550A1 (zh) 用於抑制β-內酰胺酶的組合物和方法
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
GB201512996D0 (en) Compositions and methods
PT3160263T (pt) Composições para prevenção de infeções
GB201514413D0 (en) Compositions and methods
GB201402915D0 (en) Compositions and methods